Aeterna Zentaris Inc. (NASDAQ:AEZS) Short Interest Update

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) was the recipient of a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 21,700 shares, a decline of 25.7% from the March 15th total of 29,200 shares. Based on an average trading volume of 17,300 shares, the short-interest ratio is presently 1.3 days. Currently, 0.5% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on Aeterna Zentaris in a report on Saturday, April 6th. They set a “sell” rating on the stock.

Aeterna Zentaris Trading Up 1.2 %

Shares of AEZS opened at $2.07 on Friday. The business’s 50-day moving average price is $1.94 and its 200 day moving average price is $1.92. The stock has a market capitalization of $10.06 million, a P/E ratio of -0.61 and a beta of 1.57. Aeterna Zentaris has a 1-year low of $1.36 and a 1-year high of $3.38.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.